Comparative Pharmacology
Head-to-head clinical analysis: RIFADIN versus RIMACTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIFADIN versus RIMACTANE.
RIFADIN vs RIMACTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA-dependent RNA polymerase in bacterial cells, blocking RNA transcription.
Inhibits DNA-dependent RNA polymerase in susceptible bacteria, blocking RNA transcription.
600 mg orally or intravenously once daily, or 10 mg/kg/day (max 600 mg) for tuberculosis; for meningococcal prophylaxis, 600 mg orally twice daily for 2 days.
Rifampin 600 mg orally once daily; intravenous as alternative if oral not possible.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours initially, increases to 2-5 hours after repeated dosing due to autoinduction of metabolizing enzymes; in hepatic impairment: up to 5-10 hours.
Terminal elimination half-life is 3-5 hours in adults with normal hepatic function; prolonged to 5-10 hours in hepatic impairment or obstructive jaundice. Autoinduction of metabolism reduces half-life by 20-40% after repeated dosing.
Renal: ~30% unchanged; fecal/biliary: ~60-65% as metabolites (deacetylated form) and unchanged drug; enterohepatic circulation occurs.
Primarily hepatic metabolism to deacetylated metabolite; ~60-65% of dose excreted in feces (biliary), ~15-30% in urine (unchanged and metabolites). Up to 10% via lacrimal, sweat, saliva, and other routes.
Category C
Category C
Rifamycin Antibiotic
Rifamycin Antibiotic